SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-21-020775
Filing Date
2021-02-11
Accepted
2021-02-11 16:57:55
Documents
12
Period of Report
2021-02-11
Items
Item 2.02: Results of Operations and Financial Condition

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm216271d1_8k.htm   iXBRL 8-K 24160
  Complete submission text file 0001104659-21-020775.txt   199554

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA crvs-20210211.xsd EX-101.SCH 3199
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE crvs-20210211_lab.xml EX-101.LAB 34592
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE crvs-20210211_pre.xml EX-101.PRE 22719
5 EXTRACTED XBRL INSTANCE DOCUMENT tm216271d1_8k_htm.xml XML 3723
Mailing Address 863 MITTEN ROAD SUITE 102 BURLINGAME CA 94010
Business Address 863 MITTEN ROAD SUITE 102 BURLINGAME CA 94010 (650) 900-4520
Corvus Pharmaceuticals, Inc. (Filer) CIK: 0001626971 (see all company filings)

IRS No.: 464670809 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37719 | Film No.: 21620598
SIC: 2834 Pharmaceutical Preparations